*If prior authorization is not submitted, test may be delayed.
Test Overview
All coding exons (plus 15 bp upstream and downstream of each coding exon) of the targeted gene(s) are captured, sequenced using NGS and aligned to the human reference genome. A minimum NGS coverage of 20X is achieved for all coding exons +/- 5 bp, and a minimum coverage of 10X an additional 10 bp from +/- 6 bp through +/- 15 bp. A minimum coverage of 10X is achieved for all clinically significant promoter regions. Regions which do not meet these coverage metrics are filled with targeted Sanger Sequencing. Variants in the targeted regions that are of potential clinical significance, based on the ACMG guidelines for interpretation of sequence variants (PMID: 25741868), will be reported. All reported variants of potential clinical significance not meeting the sequencing quality criteria will be confirmed by a different technology.
Analysis for the presence of CFTR mutations in patients with CFTR-related disorders affecting the respiratory tract, pancreas, sweat glands, intestine, male genital tract, and liver; confirmation of a diagnosis of Cystic Fiborsis for patients who had no mutations detected in a targeted mutation analysis for the 23 CF mutations recommended by ACMG/ACOG but have a clinical presentation consistent with Cystic Fibrosis. Ordering the CFDXL diagnostic test before ordering this assay is recommended, especially for patients of Western European ancestry. This assay is also used to confirm a diagnosis of CFTR-related Congenital Absence of the Vas Deferens (CAVD). See GeneReviews CFTR-Related Disorders for additional details about Cystic Fibrosis.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
This assay will not detect large deletions in the CFTR gene or intronic mutations outside the region sequenced in the CFTR gene.
Test Details
21 - 28 days
- CFTRSS
- CFTR Gene Seq Shadow
- CFTR
- CFTR Gene Sequencing
- Cystic Fibrosis Gene Sequencing
- Congenital Absence of the Vas Deferens (CAVD)
Specimen Requirements
Please note that ordering the Cystic Fibrosis Diagnostic Mutation Detection assay is recommended prior to the CFTR Gene Sequencing assay, especially for patients of Western European ancestry. Collect specimen in a lavender top tube. Send intact specimen within 24 hours if stored at room temperature or within 5 days if stored refrigerated. Include the patient's family history, pedigree, and ethnicity on the test requisition. Obtaining informed consent from the patient prior to genetic testing is strongly recommended. If desired, a UMHS Request and Consent for Genetic Testing form can be obtained from the MMGL Molecular Genetics Laboratory by contacting the MLabs Client Services Center at 800-862-7284 or online at https://mlabs.umich.edu/media/188.
Additional Information
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes medical geneticist interpretation of results billed as a separate additional charge. This test is not available without interpretation.